How can erythropoietin requirements be reduced in dialysis patients?
Kotanko
Peter
P
Renal Research Institute, New York, New York 10128, USA.
Levin
Nathan W
NW
Fishbane
Steven
S
Tarng
Der-Cherng
DC
Berns
Jeffrey S
JS
D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001205:Ascorbic Acid / Q000627:therapeutic use; D002331:Carnitine / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000009:adverse effects; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000502:physiology; D015314:Dialysis Solutions / Q000009:adverse effects / Q000592:standards; D004305:Dose-Response Relationship, Drug; D004340:Drug Contamination; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control; D007262:Infusions, Intravenous; D007501:Iron / Q000627:therapeutic use; D011994:Recombinant Proteins; D006435:Renal Dialysis; D014803:Vitamin B Complex / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use; D018508:Water Purification / Q000592:standards
D016207:Cytokines; D015314:Dialysis Solutions; D011994:Recombinant Proteins; D014815:Vitamins; D004921:Erythropoietin; D014803:Vitamin B Complex; D007501:Iron; D001205:Ascorbic Acid; D002331:Carnitine